Abstract
Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Volume: 9 Issue: 3
Author(s): M. I. Panadero, M. C. Gonzalez, E. Herrera and C. Bocos
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Abstract: Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Export Options
About this article
Cite this article as:
Panadero I. M., Gonzalez C. M., Herrera E. and Bocos C., Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187153009789044356
DOI https://dx.doi.org/10.2174/187153009789044356 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Current Gene Therapy Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Early Occurrence Cases of Diabetes Mellitus: Clinical Picture in Two Major Tertiary Care Hospitals in India
Current Diabetes Reviews Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Confocal Laser Scanning Microscope, Raman Microscopy and Western Blotting to Evaluate Inflammatory Response after Myocardial Infarction
Current Vascular Pharmacology Clinical Application of Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
Recent Patents on Medical Imaging Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition